A Comparison of the Efficacy and Side Effect of Lansoprazole, Various Antibiotics and Ecabet Sodium Therapy for Eradication of Helicobacter pylori

Abstract

To evaluate the potential benefit of a 2-week regimen including lansoprazole, various antibiotics and ecabet sodium for eradication of H. pylori from the gastric mucosa.
Ninety eight patients with H. pylori infection with gastric ulcer (33 patients, mean age 56) , duodenal ulcer (23 patients, mean age 48) , and chronic gastritis (42 patients, mean age 56) were included in a randomised open pilot study ; they were treated with lansoprazole 30mg od + amoxicillin 500mg qid (LPZ+AMPC) , lansoprazole 30mg od + amoxicillin 500mg qid + ecabet sodium 1ｇ bid (LPZ+AMPC+ES) , lansoprazole 30mg od + roxithromycin 150mg bid (LPZ+RXM) , or lansoprazole 30mg od + clarithromycin 400mg bid (LPZ+CAM) for 2 weeks. Endoscopy was performed before and 3 months post-treatment. The presence of H. pylori was assessed in ulcer-border, antral and corporeal biopsies by rapid urease test (CLO test) and histology (Acridine-orange stain+HP monoclonal-antibody stain) .
H. pylori eradication was observed in 27/43 (63%) in the LPZ+AMPC group, in 22/29 (76%) in the LPZ+AMPC+ES group, in 4/19 (21%) in the LPZ+RXM group, and in 3/7 (43%) in the LPZ+CAM group. Six patients reported side effects including ; diarrhea (4) , urticaria (1) in the LPZ+AMPC group, and diarrhea (1) in the LPZ+RXM group. Because of the highest eradication rate and no side effect of the LPZ+AMPC+ES therapy, we recommend it as first-line anti H. pylori treatment for a patient with H. pylori infection.